Pharmaceutical care in the treatment of acute respiratory viral infections: the phytoneering possibilities from the perspective of evidence-based medicine

For many years, acute respiratory viral infections and influenza have remained a serious medical and social health problem as a leading cause of missing days at work by adults and schools or kindergartens by children, increased costs of medical care and complications. Therefore, to date, the prevention, treatment and avoidance of complications demand new therapeutic methods based on a systemic scientific approach and aimed at reducing the disease duration, improving the quality of life of the patient and reducing the risks of dangerous consequences. The combined herbal medicine Imupret® created with the unique concept of phytoneering has significant advantages for solving the problem of the common cold and flu. The efficacy and safety of Imupret® has been confirmed by a number of clinical studies that prove its complex effect on the course of acute upper respiratory tract infections, prevention of their recurrence and reduction of the need for antibiotic therapy, which is very important in the context of the worsening global problem of antibiotic resistance. The complex composition of Imupret® provides several pharmacological effects: maintenance of the immune response activity, the anti-inflammatory action and the mucosal edema reduction, the antiviral and antibacterial effect, as well as the detoxifying action. Imupret® has immune rehabilitation properties and increases the resistance of the human body, in particular thanks to normalization of microbiocenosis and the functioning of various immune defense elements, including local factors. The adaptive and immunoregulatory properties of Imupret® provide the immune modulating effect without “traumatic” effects on the immune system and other side effects unlike most synthetic immune stimulators. Imupret® is characterized by high safety of use, particularly in children, the drug reduces the frequency of cold, relieve of the illness and its duration, improves the quality of life of patients. Imupret® is available in the form of tablets and drops for oral use, it allows to choose a rational dosage form taking into account age, occupational characteristics, compliance, ease of administration, psychological factors and individual preferences.Conclusions. According to the evidence data review, the prescription of Imupret® for the treatment and prevention of complications and relapses of acute respiratory viral infections is rational due to the complex action focused on all links of pathogenesis, namely antiviral, actibacterial, anti-inflammatory, immune modulating effects.